BioCatalyst

Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab — catalyst calendar

1 verified catalyst event(s) referencing Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-08-12
in 2mo
ESTIMATED
 READOUT
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects Wi
Phase 2 · Ovarian Cancer
 USWM CT, LLC Autologous genetically modified ADP-A2M4 ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.